Last updated: 2026-09-09 04:30:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Harmony Biosciences Holdings, Inc. (HRMY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $42.04, with a market capitalization of $2.46B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25.52 to $43.49. This page covers its latest market performance, valuation, price trends and company information.
$2.46B | |
$42.20 | |
$62.09 | |
$18.61 | |
$42.25 | |
1.59M | |
816.66K | |
-- | |
$43.49 | |
$25.52 | |
-- | |
-- |
Harmony Biosciences Holdings, Inc. (HRMY) last closed at $42.25 as of 2026-09-08 23:51:00, unchanged from the previous close of $42.25.
During the latest regular trading session, HRMY traded between $18.61 and $62.09, with a volume of 1.59M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Harmony Biosciences Holdings, Inc. (HRMY) moved from $39.87 to $42.04, representing a gain of 5.45% ($2.17).
The stock traded between $38.97 and $43.49 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 782.14 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 92.0%
HRMY is currently trading at $42.04, placing it 92.0% of the way from its 52-week low of $25.52 to its 52-week high of $43.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harmony Biosciences Holdings, Inc. (HRMY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.